Qiannan Gao
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants.
Journal: Clinical and translational science
Published: December 07, 2025
Unravelling the human disposition of [14C]-vebreltinib: Faecal recovery of parent drug and a major circulating metabolite defines its mass balance profile.
Journal: British journal of clinical pharmacology
Published: December 01, 2025
GYG1 as a Dual Biomarker of Glucagon-Like Peptide-1 Receptor Agonist Weight-Loss Response: Findings from an Integrative Multi-Omics Substudy of a Phase II Trial.
Journal: Endocrinology and metabolism (Seoul, Korea)
Published: September 03, 2025
GYG1 as a Dual Biomarker of Glucagon-Like Peptide-1 Receptor Agonist Weight-Loss Response: Findings from an Integrative Multi-Omics Substudy of a Phase II Trial.
Journal: Endocrinology and metabolism (Seoul, Korea)
Published: September 03, 2025
Integration of spatial and single-cell transcriptomic analysis uncovers cellular and molecular alterations in the hypertensive brain.
Journal: Life sciences
Published: August 17, 2025
A Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-101, an RNAi Therapeutic Targeting HBV Infection.
Journal: Clinical pharmacology in drug development
Published: December 11, 2024
Copy number loss Of APP cause thoracic aortic dissection.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: October 19, 2024
Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects.
Journal: Clinical and translational science
Published: April 10, 2024
Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
Journal: The Journal of infection
Published: August 01, 2023
Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension.
Journal: Chinese medical journal
Published: April 07, 2023
Kidney microbiota dysbiosis contributes to the development of hypertension.
Journal: Gut microbes
Published: November 12, 2022
Last Updated: 09/26/2026